公开(公告)号：US20210008062A1

公开(公告)日：2021-01-14

申请号：US17032934

申请日：2020-09-25

申请人： Orexo AB

发明人： Andreas Fischer

IPC分类号： A61K31/485 ,  A61K9/14 ,  A61K9/20 ,  A61K9/00 ,  A61K31/4748

摘要： There is provided pharmaceutical compositions for the treatment of e.g. opioid dependency comprising microparticles of a pharmacologically-effective amount of buprenorphine, or a pharmaceutically-acceptable salt thereof, in associative admixture with particles comprising a weak acid, or particles comprising weakly-acidic buffer forming materials. The composition may further comprise a disintegrant and/or particles of a pharmacologically-effective amount of naloxone, or a pharmaceutically-acceptable salt thereof. The compositions are useful in the treatment of opioid dependency/addiction and/or pain.

公开(公告)号：US20210008059A1

公开(公告)日：2021-01-14

申请号：US16939660

申请日：2020-07-27

申请人： Orexo AB

发明人： Jonas Sävmarker ,  Robert Rönn ,  Andreas Fischer

IPC分类号： A61K31/485 ,  A61K9/16 ,  A61K9/00

摘要： According to the invention, there is provided a solid pharmaceutical composition formulation for nasal delivery of an opioid antagonist, comprising a pharmacologically-effective amount of an opioid antagonist and a pharmaceutically-acceptable carrier. The compositions are preferably in the form of a powder produced by spray-drying, which are subsequently loaded into single use nasal applicators. Preferred pharmaceutically-acceptable carriers in this regard include disaccharides (e.g. lactose or trehalose) and dextrins (e.g. cyclodextrins or maltodextrins), preferably spray-dried together in combination. Compositions may further comprise an alkyl saccharide, preferably a sucrose ester, such as sucrose monolaurate. The compositions and applicators may be employed in the treatment of opioid overdose in subjects.

公开(公告)号：US10729687B1

公开(公告)日：2020-08-04

申请号：US16876468

申请日：2020-05-18

申请人： Orexo AB

发明人： Jonas Sävmarker ,  Robert Rönn ,  Andreas Fischer

IPC分类号： A61K9/14 ,  A61K31/485 ,  A61K9/16 ,  A61K9/00

摘要： According to the invention, there is provided a solid pharmaceutical composition formulation for nasal delivery of an opioid antagonist, comprising a pharmacologically-effective amount of an opioid antagonist and a pharmaceutically-acceptable carrier. The compositions are preferably in the form of a powder produced by spray-drying, which are subsequently loaded into single use nasal applicators. Preferred pharmaceutically-acceptable carriers in this regard include disaccharides (e.g. lactose or trehalose) and dextrins (e.g. cyclodextrins or maltodextrins), preferably spray-dried together in combination. Compositions may further comprise an alkyl saccharide, preferably a sucrose ester, such as sucrose monolaurate. The compositions and applicators may be employed in the treatment of opioid overdose in subjects.

公开(公告)号：US10653690B1

公开(公告)日：2020-05-19

申请号：US16506023

申请日：2019-07-09

申请人： Orexo AB

发明人： Jonas Sävmarker ,  Robert Rönn ,  Andreas Fischer

IPC分类号： A61K31/485 ,  A61K9/16 ,  A61K9/00

摘要： There is provided a solid pharmaceutical composition formulation for nasal delivery of an opioid antagonist. The pharmaceutical composition includes a pharmacologically-effective amount of an opioid antagonist and a pharmaceutically-acceptable carrier. The pharmaceutical composition is preferably in the form of a powder produced by spray-drying, which is subsequently loaded into single use nasal applicators. Preferred pharmaceutically-acceptable carriers include disaccharides (e.g. lactose or trehalose) and dextrins (e.g. cyclodextrins or maltodextrins), preferably spray-dried together in combination. The pharmaceutical composition may further comprise an alkyl saccharide, preferably a sucrose ester, such as sucrose monolaurate. The compositions and applicators may be employed in the treatment of opioid overdose in subjects.

公开(公告)号：US20190054080A1

公开(公告)日：2019-02-21

申请号：US16050592

申请日：2018-07-31

申请人： Orexo AB

发明人： Andreas Fischer

IPC分类号： A61K31/485 ,  A61K9/20 ,  A61K9/00 ,  A61K31/4748 ,  A61K9/14

摘要： There is provided pharmaceutical compositions for the treatment of e.g. opioid dependency comprising microparticles of a pharmacologically-effective amount of buprenorphine, or a pharmaceutically-acceptable salt thereof, in associative admixture with particles comprising a weak acid, or particles comprising weakly-acidic buffer forming materials. The composition may further comprise a disintegrant and/or particles of a pharmacologically-effective amount of naloxone, or a pharmaceutically-acceptable salt thereof. The compositions are useful in the treatment of opioid dependency/addiction and/or pain.

公开(公告)号：US20180042920A1

公开(公告)日：2018-02-15

申请号：US15499645

申请日：2017-04-27

申请人： Orexo AB

发明人： Andreas Fischer

IPC分类号： A61K31/485 ,  A61K9/14 ,  A61K31/4748 ,  A61K9/20 ,  A61K9/00

CPC分类号： A61K31/485 ,  A61K9/0056 ,  A61K9/006 ,  A61K9/14 ,  A61K9/20 ,  A61K9/2013 ,  A61K9/2018 ,  A61K9/2054 ,  A61K9/2077 ,  A61K9/2095 ,  A61K31/4748

摘要： There is provided pharmaceutical compositions for the treatment of e.g. opioid dependency comprising microparticles of a pharmacologically-effective amount of buprenorphine, or a pharmaceutically-acceptable salt thereof, in associative admixture with particles comprising a weak acid, or particles comprising weakly-acidic buffer forming materials. The composition may further comprise a disintegrant and/or particles of a pharmacologically-effective amount of naloxone, or a pharmaceutically-acceptable salt thereof. The compositions are useful in the treatment of opioid dependency/addiction and/or pain.

公开(公告)号：US20170246161A1

公开(公告)日：2017-08-31

申请号：US15355140

申请日：2016-11-18

申请人： Orexo AB

发明人： Andreas Fischer

IPC分类号： A61K31/485 ,  A61K9/20 ,  A61K9/00

CPC分类号： A61K31/485 ,  A61K9/0056 ,  A61K9/006 ,  A61K9/14 ,  A61K9/20 ,  A61K9/2013 ,  A61K9/2018 ,  A61K9/2054 ,  A61K9/2077 ,  A61K9/2095 ,  A61K31/4748

摘要： There is provided pharmaceutical compositions for the treatment of e.g. opioid dependency comprising microparticles of a pharmacologically-effective amount of buprenorphine, or a pharmaceutically-acceptable salt thereof, in associative admixture with particles comprising a weak acid, or particles comprising weakly-acidic buffer forming materials. The composition may further comprise a disintegrant and/or particles of a pharmacologically-effective amount of naloxone, or a pharmaceutically-acceptable salt thereof. The compositions are useful in the treatment of opioid dependency/addiction and/or pain.

公开(公告)号：US09597281B2

公开(公告)日：2017-03-21

申请号：US13870737

申请日：2013-04-25

申请人： Orexo AB

发明人： Anders Pettersson ,  Christer Nystrom ,  Susanne Bredenberg

IPC分类号： A61K9/00 ,  A61K31/44

CPC分类号： A61K9/0002 ,  A61K31/44

摘要： There is provided a formulation suitable for transmucosal administration comprising a short acting hypnotic drug, which formulation provides a measurable plasma concentration of drug within 10 minutes of administration. The formulation is capable of providing sleep on demand, and preferably comprises particles of drug, for example zolpidem or a pharmaceutically-acceptable salt thereof and a mucoadhesion promoting agent, such as sodium carboxymethylcellulose, which particles of drug and mucoadhesive are presented upon the surface of larger carrier particles.

公开(公告)号：US20160151351A1

公开(公告)日：2016-06-02

申请号：US14755091

申请日：2015-06-30

申请人： Orexo AB

发明人： Anders Pettersson

IPC分类号： A61K31/485 ,  A61K9/00 ,  A61K31/4468 ,  A61K9/16

CPC分类号： A61K31/485 ,  A61K9/006 ,  A61K9/14 ,  A61K9/167 ,  A61K9/1676 ,  A61K9/2077 ,  A61K9/5084 ,  A61K31/4468

摘要： There is provided pharmaceutical compositions for the treatment of pain comprising a pharmacologically-effective amount of an opioid analgesic, or a pharmaceutically-acceptable salt thereof, presented in particulate form upon the surfaces of carrier particles comprising a pharmacologically-effective amount of an opioid antagonist, or a pharmaceutically-acceptable salt thereof, which carrier particles are larger in size than the particles of the opioid analgesic. The compositions are also useful in prevention of opioid abuse by addicts.

公开(公告)号：US09259421B2

公开(公告)日：2016-02-16

申请号：US14668973

申请日：2015-03-25

申请人： Orexo AB

发明人： Andreas Fischer

IPC分类号： A61K31/4748 ,  A61K9/14 ,  A61K31/485 ,  A61K9/20 ,  A61K9/00

CPC分类号： A61K31/485 ,  A61K9/0056 ,  A61K9/006 ,  A61K9/14 ,  A61K9/20 ,  A61K9/2013 ,  A61K9/2018 ,  A61K9/2054 ,  A61K9/2077 ,  A61K9/2095 ,  A61K31/4748

摘要： There is provided pharmaceutical compositions for the treatment of e.g. opioid dependency comprising microparticles of a pharmacologically-effective amount of buprenorphine, or a pharmaceutically-acceptable salt thereof, in associative admixture with particles comprising a weak acid, or particles comprising weakly-acidic buffer forming materials. The composition may further comprise a disintegrant and/or particles of a pharmacologically-effective amount of naloxone, or a pharmaceutically-acceptable salt thereof. The compositions are useful in the treatment of opioid dependency/addiction and/or pain.